Genfit SA appointed Mazars to perform the financial, tax and social due diligence of Versantis AG

2022 | French biopharmaceutical company Genfit SA (Nasdaq and Euronext: GNFT), which specialises in improving the lives of patients with severe chronic liver diseases, has completed the acquisition of Versantis AG. Mazars was mandated for the financial, tax and social due diligence of the target.

At the level of Genfit SA, this acquisition aims to consolidate its position in the field of acute and chronic liver failure (ACLF) through the integration of a clinically advanced asset (VS-01) with a solid scientific rationale supported by encouraging Phase 1b and preclinical data. Additionally, Genfit SA will also expand its pipeline in other liver diseases with significant unmet medical needs through other product candidates developed by Versantis AG.

Genfit SA was advised by a Mazars team composed of Baudouin Heron and Antonio Rubino for the financial part and Murielle Kammermann and Isabelle Bugnon for the tax and social part.

Want to know more?